[1]叶苗青,唐颖慧,杨跃青,等.恩替卡韦联合乙转灵治疗乙型肝炎肝纤维化患者LSM值与中医证候积分的相关性研究[J].西部中医药,2023,36(10):112-115.[doi:10.12174/j.issn.2096-9600.2023.10.23]
　YE Miaoqing,TANG Yinghui,YANG Yueqing,et al.Study on the Correlation between LSM Values and TCM Syndrome Scores in Patients with Hepatitis B Hepatic Fibrosis Treated with Entecavir and Yizhuanling[J].Western Journal of Traditional Chinese Medicine,2023,36(10):112-115.[doi:10.12174/j.issn.2096-9600.2023.10.23]
点击复制

恩替卡韦联合乙转灵治疗乙型肝炎肝纤维化患者LSM值与中医证候积分的相关性研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年10期
页码:
112-115
栏目:
出版日期:
2023-10-15

文章信息/Info

Title:
Study on the Correlation between LSM Values and TCM Syndrome Scores in Patients with Hepatitis B Hepatic Fibrosis Treated with Entecavir and Yizhuanling
作者:
叶苗青, 唐颖慧, 杨跃青, 何瑾瑜, 薛敬东, 李粉萍
陕西省中医医院，陕西 西安 710003
Author(s):
YE Miaoqing, TANG Yinghui, YANG Yueqing, HE Jinyu, XUE Jingdong, LI Fenping
Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an 710003, China
关键词:
乙型肝炎肝纤维化; 恩替卡韦; 乙转灵; 瞬时弹性扫描; 肝胆硬度值; 中医证候
Keywords:
hepatitis B liver fibrosis; entecavir; fibroscan; liver stiffness measurement; TCM syndromes
分类号:
R575.2
DOI:
10.12174/j.issn.2096-9600.2023.10.23
文献标志码:
B
摘要:
目的观察恩替卡韦联合乙转灵治疗乙型肝炎肝纤维化患者中医证候与瞬时弹性扫描（Fibroscan）检测肝脏硬度值（liver stiffness measurement，LSM）之间的相关性。 方法将80例乙型肝炎肝纤维化患者按单盲随机方法分成对照组和观察组，每组各40例，对照组予以恩替卡韦分散片治疗24周，观察组在对照组治疗基础上给予乙转灵片治疗24周，所有患者均整理中医证候积分和Fibroscan检测结果，按肝肾亏损、脾虚挟瘀型中医辨证标准进行分型，同时用LSM值的形式来表达肝脏瞬时弹性硬度值，并且分析中医证候与肝脏瞬时弹性硬度LSM值二者之间的关系。 结果观察组治疗12、24周时LSM值较治疗前显著下降（P＜0.05）；对照组治疗24周时LSM值较治疗前明显下降（P＜0.05）；与对照组比较，观察组12、24周时LSM值明显降低（P＜0.05）；治疗24周时，观察组LSM值与中医证候积分均明显降低，且总有效率越高，LSM值越低。 结论恩替卡韦联合乙转灵治疗乙型肝炎肝纤维化患者疗效满意，且乙型肝炎肝纤维化患者Fibroscan检测LSM值与中医证候积分、总有效率之间存在相关性，且具有一致性，可判断肝纤维化病情，评估治疗效果，对肝纤维化诊治具有重要的临床意义。
Abstract:
ObjectiveTo observe the relationship between TCM syndrome and LSM detected by Fibroscan in patients with hepatitis B liver fibrosis treated with entecavir and Yizhuanling. MethodsAll 80 patients were divided into the control group and the observation group according to single-blind randomised method, with 40 cases in each group, the control group was administered with entecavir dispersible tablets for 24 weeks, and the observation group was given Yizhuanling tablets for 24 weeks based on the therapy accepted by the control group . After sorting out TCM syndrome integrals and Fibroscan detection results, all the patients were grouped into liver and kidney depletion, spleen deficiency mixed with stagnation in light of TCM syndrome differentiation standards, while LSM was used to express liver transient elastic stiffness values, to analyze the relationship between TCM syndrome integrals and LSM. ResultsThe LSM of the observation group decreased significantly after 12 and 24 weeks of the treatment compared with that before treatment (P<0.05); LSM of the control group lowered remarkably after 24 weeks of the treatment than before the treatment (P<0.05); compared with the control group, LSM values of the observation group decreased obviously after 12 and 24 weeks of the treatment (P<0.05); after 24 weeks of the treatment, LSM values and TCM syndrome integrals of the observation group cut down clearly, the higher total effective rate was, the lower LSM was. ConclusionEntecavir and Yizhuanling could achieve satisfactory clinical effects in the treatment of hepatitis B liver fibrosis, LSM value detected by Fibroscan is consistent with TCM syndrome and total effective rate, which could be used to judge the condition of liver fibrosis and evaluate the therapeutic effects, it is of clinical significance in the diagnosis and treatment of liver fibrosis.

相似文献/References:

[1]朱梦佳,蔡萌强,杨慧萍,等.小柴胡汤联合恩替卡韦治疗慢性乙型病毒性肝炎的Meta分析[J].西部中医药,2021,34(12):62.[doi:10.12174/j.issn.2096-9600.2021.12.17]
　ZHU Mengjia,CAI Mengqiang,YANG Huiping,et al.Meta Analysis of Xiaochaihu Decoction and Entecavir in the Treatment of Chronic Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2021,34(10):62.[doi:10.12174/j.issn.2096-9600.2021.12.17]

备注/Memo

备注/Memo:
叶苗青（1989—），男，博士学位，副主任医师。研究方向：中西结合防治肝病的基础与临床研究。2018年国家中医药管理局区域中医（肝病）诊疗中心培育单位建设项目［国中医药办医政函〔2017〕39号］；陕西省感染性疾病临床医学研究中心（中西医结合）建设项目（2020LCZX-02）。
更新日期/Last Update: 1900-01-01